Awareness • Early Detection • Treatment • Research • Survivorship

Thierry Jahan, M.D., University of California San Francisco

Thierry Jahan, M.D. is the one of the region’s foremost and highly regarded thoracic oncologists. Dr. Jahan has devoted his life to treating patients with lung cancer, mesothelioma and sarcoma. In addition to his keen clinical insight, Dr. Jahan is known by patients, their families and fellow clinicians for his sense of empathy and compassion. His commitment to wiping out lung cancer can be seen in the pins and ribbons that adorn his white coat, a message of hope he carries symbolically to patients as they battle a cruel disease.

Dr. Jahan received his M.D. from George Washington University. He completed his residency and an internal medicine fellowship at Cedars Sinai Medical Center in Los Angeles, followed by a fellowship in hematology and oncology at UCSF. In 1994, Dr. Jahan joined the UCSF faculty and later, with Dr. David M. Jablons, cofounded the Thoracic Oncology Program. Dr. Jahan currently holds the title of Associate Professor of Medicine at the UCSF School of Medicine.

Dr. Jahan has been the recipient of numerous awards including the Medical House Staff Outstanding Teacher Award and Friend of the Palliative Care Service Award. He is also a member of numerous professional organizations, including the American College of Physicians, American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC) and the Association of Northern California Oncologists.
Dr. Jahan has authored or co-authored numerous peer-reviewed articles, book chapters and research abstracts and lectured nationally and internationally on lung cancer and mesothelioma. The San Francisco Chronicle, Time Magazine and KPIX in San Francisco have each sought out his insights and observations on the clinical and human side of battling serious life-threatening cancers.
Research Summary

Dr. Jahan is Principal Investigator on numerous thoracic oncology clinical trials. He has a particular interest in testing target therapies in non-small cell lung cancer malignant mesothelioma as either single agents or in combination with chemotherapy and/or radiation.

Thierry Jahan, M.D., University of California San Francisco from TEAM DRAFT on Vimeo.